Evaluating SHR-1703 for Eosinophilic Granulomatosis With Polyangiitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the efficacy and safety of SHR-1703 in patients diagnosed with Eosinophilic Granulomatosis With Polyangiitis (EGPA). It is designed as a phase 2/3 interventional study, where participants will receive either SHR-1703 or a placebo. Eligible participants must be adults with a history of relapsing or refractory EGPA and stable doses of oral prednisone. The study will monitor the treatment's effects over a specified period to determine its potential benefits and safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female subjects age 18 years or older;
2. Diagnosed with EGPA for at least 6 months;
3. History of relapsing or refractory EGPA；
4. Stable dose of oral prednisone of ≥7.5 mg/day (but not \>50 mg/day) for at least 4 weeks prior to randomization;
5. If receiving immunosuppressive therapy (excluding cyclophosphamide), the dosage must be stable within 4 weeks prior to randomization and during the study.

Exclusion Criteria:

1. Subjects with other eosinophilic-related diseases;
2. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
3. Life-threatening EGPA within 3 months prior to randomization;
4. Malignancy history within 5 years prior to randomization;
5. Immunodeficiency;
6. Uncontrolled hypertension；
7. Uncontrolled cerebrovascular and cardiovascular disease;
8. parasitic infection within 6 months prior to randomization;
9. Active infectious disease requiring clinical treatment within 4 weeks prior to randomization;
10. Subjects with a dose of oral prednisone of \>50 mg/day within 4 weeks prior to randomization;
11. Oral or intravenous cyclophosphamide therapy within 4 weeks prior to randomization;
12. Intravenous or subcutaneous immunoglobulin within 12 weeks prior to randomization;
13. Biological agents or TH2 cytokine inhibitors used within 12 weeks prior to randomization or within 5 half-lives of the drug;
14. Rituximab used within 6 months prior to randomization；
15. Surgical plans that might affect the evaluation;
16. Significant laboratory abnormalities；
17. Prolonged QTc interval or other electrocardiogram abnormalities with significant safety risk at screening;
18. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;
19. Subjects participated another clinical study and received active drug within 30 days or 5 half-lives of the drug prior to screening;
20. Subjects is pregnant, lactating, or planning to be pregnant;
21. Subjects have a known history of hypersensitivity or intolerance to anti-IL-5 mabs or other biological agents or previous failure of IL-5/IL-5R therapy;
22. Other conditions unsuitable for participation in the study per investigator judgement.

Where it's running

• Beijing Hospital
  Beijing, Beijing Municipality, China Recruiting
• The Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Siai Sun
• Email: siai.sun@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collection of tissue samples for vasculitis research

  This study is collecting tissue samples from patients with vasculitis to see if they can help researchers understand the disease better and find new ways to diagnose and treat it.

  Recruiting at 3 sites University of Pennsylvania · Boston, Massachusetts and 7 other locations · NCT02967068

• Long-term observation of Eosinophilic Granulomatosis With Polyangiitis

  This study is trying to find new ways to track how Eosinophilic Granulomatosis With Polyangiitis affects people over time by looking at their health and collecting samples.

  Recruiting at 6 sites University of Pennsylvania · San Diego, California and 14 other locations · NCT00315380

• Safety test of SHR-7590 in healthy adults and adults with moderate-to-severe inflammatory bowel disease

  This early human study tests whether SHR-7590 is safe and tolerable in healthy adults and in adults with moderate-to-severe inflammatory bowel disease.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Hangzhou, Zhejiang · NCT07758101

• A single-dose SHR-7012 safety study in healthy adults

  This study tests a single dose of SHR-7012 to see if it is safe and how it behaves in the body of healthy adults.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Hangzhou, Zhejiang · NCT07749651

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

• HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults

  This study tests whether HRS-9821 inhalation can be safely taken and help people with moderate to severe COPD, and aims to find a reasonable dose.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07640451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.